A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
European Journal of Cancer2013Vol. 49(6), pp. 1287–1296
Citations Over TimeTop 1% of 2013 papers
Cora N. Sternberg, Robert E. Hawkins, John Wagstaff, Pamela Salman, Jozef Mardiak, Carlos H. Barrios, Juan José Zarbá, Oleg Gladkov, Eunsik Lee, Cezary Szczylik, Lauren McCann, Stephen D. Rubin, Mei Chen, Ian D. Davis
Related Papers
- → Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma(2016)3 cited
- → Identification of biomarkers in pazopanib treated patients with renal cell carcinoma.(2013)1 cited
- → One year survivor of metastatic renal cell carcinoma treated with pazopanib(2017)1 cited
- → Case Report of a Long-surviving Man with Metastatic Renal Cell Carcinoma Treated with Pazopanib(2014)1 cited
- → Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.(2014)